Fig. 1From: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspectiveProbabilistic sensitivity analysis results for a base case, and b ITT analysis. ITT, intent-to-treat; QALY, quality-adjusted life-yearBack to article page